Has There Been A Sea Change In Trial Diversity Efforts?
Executive Summary
PhRMA partnered with Deloitte to produce a report that included a survey of 31 member companies indicating that most had made significant investments in improving clinical trial diversity.
You may also be interested in...
Clinical Trial Diversity: PhRMA, Academia Lay Foundation For Network Of Community-Based Sites
PhRMA is funding an initiative to establish a network of sustainable, community-based trial sites. During 18-month proof of concept phase, 10 sites will receive training, technical support and mentorship.
OCE ‘Project’ To Help Understand Trial Site Selection, Also May Inform Policy
Project Site Selector will allow FDA Oncology Center of Excellence staff to discuss site selection process with industry and potentially help improve clinical trial diversity efforts.
Could The US FDA Set Clinical Trial Diversity Minimums?
Oncology Center of Excellence Director Richard Pazdur asked whether the FDA should have more conversations with sponsors about site selection and percentages of US participants.